Last reviewed · How we verify

NCT04431882

The Role of Optic Nerve Sheath Fenestration in Leukemic Patients Having Increased Intracranial Pressure

Status unknown Phase 2, PHASE3 Last updated 16 June 2020
What this trial tests

Phase 2, PHASE3 trial testing optic nerve sheath fenestration in Leukemic Patients With Increased Intracranial Pressure in 20 participants. Status unknown.

Timeline
1 June 2019
Primary endpoint
10 June 2020
30 June 2020

Quick facts

Lead sponsorAlexandria University
PhasePhase 2, PHASE3
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date1 June 2019
Primary completion10 June 2020
Estimated completion30 June 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Alexandria University

Who can join

Adults 6 to 18, any sex, with Leukemic Patients With Increased Intracranial Pressure or Optic Nerve Sheath Fenestration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Optic nerve sheath fenestration (ONSF) first described by De Wecker in 1872 for the treatment of neuroretinitis. Since then, optic nerve sheath fenestration has become well established procedure for treatment of papilledema in medically uncontrolled patients of idiopathic intracranial hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Alexandria University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04431882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing